Business Case

Fast-to-market opportunity assessment of an orphan disease with a pipeline oncology drug

Our client, a top biotechnology company, wanted to understand whether pursuing an orphan disease as the first indication with one of their pipeline drugs would bring it to market faster versus only focusing on its main cancer indication. LSC was able to identify and analyze several analog case studies, glean speed-to-market potential, and synthesize key considerations and implications for the client team. Project results prompted the decision to initiate a Phase 1/2 study in target orphan disease.